D Niederwieser
Overview
Explore the profile of D Niederwieser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
5377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loke J, Labopin M, Craddock C, Niederwieser D, Cornelissen J, Afansayev B, et al.
Bone Marrow Transplant
. 2020 Oct;
56(3):614-621.
PMID: 33009514
Patients with acute myeloid leukaemia (AML) who lack a matched sibling or unrelated donor commonly undergo transplantation from a donor matched at 9/10 HLA-A, -B, -C, -DRB1, -DQB1 alleles, and...
2.
Hochhaus A, Baccarani M, Silver R, Schiffer C, Apperley J, Cervantes F, et al.
Leukemia
. 2020 Mar;
34(4):966-984.
PMID: 32127639
The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal...
3.
Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, et al.
Hematol Oncol Stem Cell Ther
. 2019 Aug;
13(1):7-16.
PMID: 31449781
The development of hematopoietic stem cell transplantation (HSCT) programs can face significant challenges in most developing countries because such endeavors must compete with other government health care priorities, including the...
4.
Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji R, et al.
J Intern Med
. 2018 Oct;
285(4):407-418.
PMID: 30372796
Background: Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years. Objectives: To assess the incremental improvement of transplanted AML...
5.
Jaimovich G, Rolon J, Baldomero H, Rivas M, Hanesman I, Bouzas L, et al.
Bone Marrow Transplant
. 2017 May;
52(5):798.
PMID: 28465623
No abstract available.
6.
Bill M, Jentzsch M, Grimm J, Schubert K, Lange T, Cross M, et al.
Bone Marrow Transplant
. 2017 Apr;
52(6):932-935.
PMID: 28368377
No abstract available.
7.
Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, et al.
Leukemia
. 2017 Mar;
31(8):1752-1759.
PMID: 28270691
Differences in major and minor histocompatibility antigens between donor and recipient trigger powerful graft-versus-host reactions after allogeneic hematopoietic stem cell transplantation (HSCT). The clinical effects of alloreactivity present a Janus-face:...
8.
Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, et al.
Eur J Cancer Care (Engl)
. 2017 Jan;
27(1).
PMID: 28134477
We investigated the impact of demographic and disease related factors on non-participation and dropout in a cluster-randomised behavioural trial in cancer patients with measurements taken between hospitalisation and 6 months...
9.
Jaimovich G, Rolon J, Baldomero H, Rivas M, Hanesman I, Bouzas L, et al.
Bone Marrow Transplant
. 2017 Jan;
52(5):671-677.
PMID: 28112744
Haematopoietic cell transplant activity in the 28 countries comprising Latin America is poorly defined. We conducted a voluntary survey of members of the Latin American Bone Marrow Transplantation Group regarding...
10.
van Gelder M, de Wreede L, Bornhauser M, Niederwieser D, Karas M, Anderson N, et al.
Bone Marrow Transplant
. 2016 Dec;
52(3):372-380.
PMID: 27941763
Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term...